# **Human Wnt-10b Antibody**

Monoclonal Mouse IgG<sub>2B</sub> Clone # 793127 Catalog Number: MAB7196


DESCRIPTION		
Species Reactivity	Human	
Specificity	Detects human Wnt-10b in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human Wnt-6 is observed.	
Source	Monoclonal Mouse IgG <sub>2B</sub> Clone # 793127	
Purification	Protein A or G purified from hybridoma culture supernatant	
Immunogen	Chinese hamster ovary cell line CHO-derived recombinant human Wnt-10b Asn29-Lys389 Accession # 000744	
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied as a 0.2 µm filtered solution in PBS.	

## **APPLICATIONS**

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

	Recommended Concentration	Sample
Western Blot	0.5 μg/mL	See Below

### DATA



Detection of Human Wnt-10b by Western Blot. Western blot shows lysates of SW480 human colorectal adenocarcinoma cell line and MDA-MB-468 human breast cancer cell line. PVDF membrane was probed with  $0.5~\mu g/mL$  of Mouse Anti-Human Wnt-10b Monoclonal Antibody (Catalog # MAB7196) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF018). A specific band was detected for Wnt-10b at approximately 50 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

### PREPARATION AND STORAGE

Reconstitution Sterile PBS to a final concentration of 0.5 mg/mL.

Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

\*Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.





# **Human Wnt-10b Antibody**

Monoclonal Mouse IgG<sub>2B</sub> Clone # 793127 Catalog Number: MAB7196

#### **BACKGROUND**

Wnt-10b (also known as Wnt-12) is a 42-44 kDa member of the Wnt family of secreted, highly conserved, cysteine-rich glycoproteins that play important roles in vertebrate pattern formation, cell fate decision, axon guidance, and tumor formation (1-3). Human Wnt-10b cDNA encodes a 389 amino acid (aa) precursor that contains a 28 aa signal sequence plus a 361 aa mature protein that contains two glycosylation sites, three potential phosphorylation sites, and a potential palmitoylation site (3, 4). Human Wnt-10b shares 97-99% aa identity with mouse, rat, equine, porcine, and canine Wnt-10b. Wnt-10b plays a critical role in maintaining mesenchymal stem cells and determining whether they differentiate to adipocytes or osteoblasts (5-7). Mouse Wnt-10b deletion produces age-dependent loss of bone mass due to defective production of osteoblasts, while transgenic over-expression increases postnatal osteoblast differentiation and inhibits adipocyte differentiation (5-7). Ectopic expression of Wnt-10b in an obesity and diabetes-prone background, such as the ob/ob mouse, inhibits obesity (8). In mouse skeletal muscle, Wnt-10b is expressed inversely with SREBP1c and increases insulin sensitivity (9). In humans, a missense polymorphism is responsible for a malformation of hands and feet, while a C256Y inactivating mutation is associated with severe early-onset obesity (10, 11). Wnt-10b is mainly produced by stem cells and pre-osteoblasts, but also by adult bone marrow CD8+T lymphocytes stimulated with parathyroid hormone (12). In some hepatocellular carcinomas, Wnt-10b can inhibit cancer cell growth, but in others, it can act synergistically with FGFs to stimulate cell growth (13). Several Wnts, including Wnt-10b, are expressed in both normal and/or malignant colon tissues (14).

### References:

- 1. Hardiman, G. et al. (1997) Cytogenet. Cell Genet. 77:278.
- 2. Katoh, M. (2008) Curr. Drug Targets 9:565.
- 3. Hausmann, G. et al. (2007) Nat. Rev. Mol. Cell Biol. 8:331.
- 4. Swiss Prot Accession # O00744.
- 5. Stevens, J.R. et al. (2010) J. Bone Miner. Res. 25:2138.
- Bennett, C.N. et al. (2007) J. Bone Miner. Res. 22:1924.
- 7. Bennett, C.N. et al. (2005) Proc. Natl. Acad. Sci. USA 102:3324.
- 8. Wright, W.S. et al. (2007) Diabetes 56:295.
- 9. Abiola, M. et al. (2009) PLoS ONE 4:e8509.
- 10. Ugur, S.A. and A. Tolun (2008) Hum. Mol. Genet. 17:2644.
- 11. Christodoulides, C. et al. (2006) Diabetologia 49:678.
- 12. Terauchi, M. et al. (2009) Cell Metab. 10:229
- 13. Yoshikawa, H. et al. (2007) Mol. Biol. Cell 18:4292.
- 14. Holcombe, R.F. et al. (2002) J. Clin. Pathol: Mol. Pathol. 55:220.

